Merck Restructures Human Health to Accelerate Launches Across a Diversified Portfolio
Merck is reorganizing its Human Health unit into two business units—Oncology and Specialty, Pharma & Infectious Diseases—to sharpen commercial execution for a broader portfolio. New leaders Jannie Oosthuizen (Oncology) and Brian Foard (Specialty, Pharma & Infectious Diseases) will report to CEO Robert Davis, while Chirfi Guindo leads Strategic Access, Policy & Communications. The move aims to better advance Merck’s widening pipeline, with about 80 Phase 3 trials and more than 20 growth drivers anticipated in the coming years.













